Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2, Multicenter, Randomized, Placebo-controlled, Double-blind Study of the Efficacy and Safety of Vamifeport in Adult Subjects With HFE-related Hereditary Hemochromatosis (FERROCLEAR Study)

NCT07332091 is registered in ClinicalTrials.gov with CSL Behring as lead sponsor.

NCT NCT07332091
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07332091 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2, Multicenter, Randomized, Placebo-controlled, Double-blind Study of the Efficacy and Safety of Vamifeport in Adult Subjects With HFE-related Hereditary Hemochromatosis (FERROCLEAR Study)
Lead sponsor
CSL Behring
Phase
Phase 2
Overall status
Recruiting
Start date
January 22, 2026
Completion date
May 15, 2028
Enrollment
84 (estimated)
Sites
100

Conditions

As the registry lists them; a condition with its own page is linked.

homeostatic iron regulator gene-related hereditary hemochromatosis